Simon H. Stertzer Acquires 22,753 Shares of BioCardia, Inc. (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon H. Stertzer acquired 22,753 shares of the stock in a transaction on Monday, March 3rd. The stock was bought at an average price of $2.30 per share, with a total value of $52,331.90. Following the completion of the acquisition, the director now directly owns 40,602 shares of the company’s stock, valued at $93,384.60. This trade represents a 127.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

BioCardia Stock Up 0.8 %

Shares of BCDA opened at $2.54 on Thursday. The company has a market capitalization of $11.64 million, a P/E ratio of -0.61 and a beta of 1.28. The firm has a 50 day moving average of $2.34 and a 200 day moving average of $2.44. BioCardia, Inc. has a twelve month low of $1.63 and a twelve month high of $6.90.

Wall Street Analysts Forecast Growth

BCDA has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a report on Wednesday, December 18th. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th.

Institutional Investors Weigh In On BioCardia

A hedge fund recently raised its stake in BioCardia stock. Geode Capital Management LLC raised its stake in shares of BioCardia, Inc. (NASDAQ:BCDA) by 110.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,987 shares of the company’s stock after buying an additional 16,251 shares during the period. Geode Capital Management LLC owned about 0.68% of BioCardia worth $68,000 as of its most recent SEC filing. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.